- Home
- RMNI vs PRLD Comparison
RMNI vs PRLD Comparison
Compare RMNI & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMNI | PRLD |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 457.2M | 529.1M |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RMNI | PRLD |
|---|---|---|
| Price | $4.61 | $5.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $5.00 | ★ $5.67 |
| AVG Volume (30 Days) | 466.2K | ★ 545.7K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 197.50 | 23.21 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $431,496,000.00 | $12,140,000.00 |
| Revenue This Year | $6.02 | $320.10 |
| Revenue Next Year | $5.50 | $100.00 |
| P/E Ratio | $115.00 | ★ N/A |
| Revenue Growth | 5.33 | ★ 73.43 |
| 52 Week Low | $2.87 | $0.98 |
| 52 Week High | $5.68 | $6.83 |
Technical Indicators
Market Signals| Indicator | RMNI | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout RMNI Rimini Street Inc. (DE)
Rimini Street Inc and its subsidiaries are providers of end-to-end enterprise software support, products, and services. The company offers a comprehensive family of unified solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize clients' enterprise applications, databases, and technology software platforms. The company derives revenues from clients by providing subscription support services for enterprise resource planning, customer relationship management, product lifecycle management, database, and technology software systems. Geographically, the company generates its revenue from the United States of America and the International market.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.